Still, while several new studies offer promising hints at the medications potential, the results show a correlational link, not a causal link
Whether any of it suits you is a question for the provider managing your treatment
A pharmacokinetic study in growth-hormone-deficient patients using a closely related long-acting IGF-1 preparation found a terminal half-life of 5.8 hours for free IGF-1 after subcutaneous dosing, though the exact value for the research-grade LR3 analogue varies by formulation [4]
Phase 3 TRIUMPH adds an intermediate 6 mg step and treats 4 mg, 9 mg, and 12 mg as target maintenance doses depending on the trial arm
After narrowing down the list of Reddit posts they analyzed 33,609 in total, from 14,595 unique accounts discussing the various side effects
In two trials, EASE and DEPICT, about 2-4% of participants experienced diabetic ketoacidosis over one year